Goldman Sachs Group Inc Apellis Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 215,999 shares of APLS stock, worth $5.14 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
215,999
Previous 307,709
29.8%
Holding current value
$5.14 Million
Previous $6.73 Million
44.45%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
132MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$291 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$283 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$242 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$232 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$214 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.61B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...